What is Hyper-CVAD?
An intensive, dose-intensive chemotherapy regimen used mainly for acute lymphoblastic leukemia (ALL) and some aggressive lymphomas (e.g., Burkitt lymphoma).
Components
- Course A (Hyper-CVAD):
- Cyclophosphamide (high dose)
- Vincristine
- Doxorubicin (Adriamycin)
- Dexamethasone
- Course B (High-dose methotrexate + cytarabine):
- Methotrexate (high dose, CNS prophylaxis)
- Cytarabine (Ara-C) (high dose)
Cycle Schedule
- Alternating Course A and Course B every 21 days
- Typically 4–8 cycles total, followed by maintenance or stem cell transplant
Indications
- Adult ALL, especially high-risk or relapsed cases
- Some aggressive lymphomas (e.g., Burkitt lymphoma)
- Sometimes used in high-grade lymphoid malignancies
Key Toxicities
- Myelosuppression: profound neutropenia, thrombocytopenia, anemia
- Neurotoxicity: vincristine-related peripheral neuropathy
- Cardiotoxicity: doxorubicin cumulative dose risk
- Mucositis and gastrointestinal toxicity
- Renal toxicity: methotrexate requires hydration and leucovorin rescue
- Tumor lysis syndrome (TLS) risk (especially with high tumor burden)
- Infections – high risk due to prolonged neutropenia
Monitoring
- CBC with differential (frequent)
- Renal and liver function tests
- Cardiac function (ejection fraction baseline and during therapy)
- Neurologic assessment (vincristine toxicity)
- Methotrexate serum levels to guide leucovorin rescue
- Electrolytes and TLS labs during therapy
Supportive Care
- Leucovorin rescue post-methotrexate
- Aggressive hydration to prevent renal toxicity
- Antimicrobial prophylaxis (bacterial, fungal, PCP)
- Growth factor support (G-CSF) may be used
Other Notes
- CNS prophylaxis via high-dose methotrexate and cytarabine courses
- Often combined with intrathecal chemotherapy
- Requires experienced oncology team and close monitoring due to toxicity